Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study
Cancer Medicine · 2024
DOI: 10.1002/cam4.7236 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Liang Qiao und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Centre, Guan…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Pyridines, Phenylurea Compounds, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Regorafenib remains the standard and widely used second‐line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large‐scale multicenter real‐world evidence concerning the concurrent use of regorafenib with immune checkpoint inhibitors (ICI). This study aims to evaluate whether combining regorafenib with ICI provides greater clinical benefit than regorafenib monotherapy as second‐line therapy for advanced HCC under real‐world circumstances. Patients and Methods The study included 208 patients from five medical facilities. One hundred forty‐three patients received regorafenib plus ICI combination therapy, while 65 patients received regorafenib monotherapy. Propensity score matching (PSM) analysis was employed.
Results
The regorafenib plus ICI group demonstrated significantly higher objective response rate (24.3% vs. 10.3%, after PSM, p = 0.030) and disease control rate (79.4% vs. 50.0%, after PSM, p < 0.001) compared to the regorafenib monotherapy group based on mRECIST criteria. Median progression‐free survival (7.9 vs. 3.2 months, after PSM, p < 0.001) and overall survival (25.6 vs. 16.4 months, p = 0.010, after PSM) were also considerably longer in the regorafenib plus ICI group. The incidence of Grades 3–4 treatment‐related adverse events (TRAEs) was marginally greater in the regorafenib plus ICI group than in the regorafenib group (23.8% vs. 20.0%, p = 0.546). Notably, there were no instances of treatment‐related mortality or emergence of new TRAEs in any treatment group.
Conclusion
The combination of regorafenib and ICI shows potential as a viable second‐line treatment for advanced HCC, exhibiting favorable efficacy while maintaining a tolerable safety profile in contrast to regorafenib monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Centre, Guangzhou, China.
- Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Hepatopancreatic Surgery, the First People's Hospital of Foshan, Foshan, China.
- Department of Oncology, Guangzhou Panyu Central Hospital, Guangzhou, China.
ORCID-Profile: Liang Qiao, Guoying Wang, Yunfei Yuan, Binkui Li
Zitieren
APA
Qiao, L., He, W., Wang, G., Chen, H., Huang, F., Zhang, B., Qiu, Y., Liu, S., Huang, Z., Yuan, Y., Qiu, J., Yuan, Y., & Li, B. (2024). Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study. Cancer Medicine. https://doi.org/10.1002/cam4.7236
Vancouver
Qiao L, He W, Wang G, Chen H, Huang F, Zhang B, et al. Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study. Cancer Medicine. 2024. doi:10.1002/cam4.7236
BibTeX
@article{Qiao2024,
author = {Qiao, Liang and He, Wei and Wang, Guoying and Chen, Huanwei and Huang, Fuxi and Zhang, Bo and Qiu, Yuxiong and Liu, Shaoru and Huang, Zhenkun and Yuan, Yichuan and Qiu, Jiliang and Yuan, Yunfei and Li, Binkui},
title = {Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7236}
}
EUVIMED